Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05117476 · ClinicalTrials.gov registry record · Phase 1

A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor and NSCLC, sponsored by Cullinan Therapeutics.

Active
Registry status
Phase 1
Development phase
440
Enrollment target
20
Study locations

NCT05117476 is a Phase 1 study of Advanced Solid Tumor and NSCLC that is active but no longer recruiting, run by Cullinan Therapeutics. The registered enrollment target is 440 participants, above the 191-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (130% higher). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05117476, a Phase 1 study of Advanced Solid Tumor and NSCLC, is active but no longer recruiting, sponsored by Cullinan Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
440 participants
Enrollment target
20
Study locations

Study Summary

CLN-619-001 is a Phase 1, open-label, multi-center study of CLN-619 alone and in combination with pembrolizumab in patients with advanced solid tumors.

Conditions Studied

Advanced Solid Tumor NSCLC

Interventions

  • DRUG Pembrolizumab
  • DRUG Paclitaxel
  • DRUG pemetrexed
  • DRUG CLN-619
  • DRUG Carboplatin AUC 6

Study Locations (20)

Other

  • Biokinetica - Józefów
  • Med-Polonia Sp. zo. o. - Poznan
  • Narodowy Insytut Onkologii im Marii Sklodowskiej-Curie - Warsaw
  • START Barcelona - Barcelona

California

  • City of Hope - Duarte
  • City of Hope - Irvine

Victoria

  • Monash Health - Clayton
  • Alfred Health - Melbourne

Alabama

  • University of Alabama at Birmingham - Birmingham

Florida

  • Florida Cancer Specialists - Sarasota

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Michigan

  • START Midwest - Grand Rapids

New Jersey

  • Hackensack Meridian Health - Hackensack

Trial Details

FieldValue
Enrollment Target 440 participants
Start Date 2021-10-29
Est. Completion 2026-06
Phase Phase 1

Sponsor

Cullinan Therapeutics

9 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05117476

The ClinicalTrials.gov registry entry for NCT05117476 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 440 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 191-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (130% higher). The listed sponsor is Cullinan Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.

NCT05117476 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Other, California, Victoria.

Frequently Asked Questions

What is clinical trial NCT05117476 about?

NCT05117476 is a clinical study titled "A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors". CLN-619-001 is a Phase 1, open-label, multi-center study of CLN-619 alone and in combination with pembrolizumab in patients with advanced solid tumors.

What is the current status of trial NCT05117476?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 440 participants. The study started on 2021-10-29. Estimated completion is 2026-06.

What conditions does trial NCT05117476 study?

This clinical trial studies the following conditions: Advanced Solid Tumor, NSCLC.

What interventions are being tested in trial NCT05117476?

The interventions under investigation include: Pembrolizumab (DRUG), Paclitaxel (DRUG), pemetrexed (DRUG), CLN-619 (DRUG), Carboplatin AUC 6 (DRUG).

Who is sponsoring clinical trial NCT05117476?

This trial is sponsored by Cullinan Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05117476 being conducted?

This trial has 20 study locations across Alabama, California, Florida, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

NSCLC

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.